AUTHORS
Saubia Fathima, MD, Abiola Bolarinwa, MBBS, MSc, FMCPath2, Abhishek Avinash Mangaonkar, MBBS3, Mark R. Litzow, MD4, Mehrdad Hefazi Torghabeh, MD5, Mrinal M. Patnaik, MD, MBBS6, Animesh Pardanani, PhD, MBBS7, Antoine N. Saliba, M.D.8, William Hogan, M.B., B.Ch.9, Mithun Shah, MD, PhD10, Naseema Gangat, MBBS11, Hassan B Alkhateeb, M.D.12, Aref Al-Kali, M.D.13, Aasiya Matin, MBBS14
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
ABSTRACT
Background
Nucleophosmin-1 (NPM1) mutations occur in approximately one-third of patients with acute myeloid leukemia (AML) and are associated with favorable prognosis, however, relapse remains a concern. Type A variants account for the vast majority of NPM1 mutations, while the clinical significance of less common non-A/B/D (non-ABD) subtypes remains uncertain. We evaluated the clinical, molecular, and prognostic correlates of NPM1 mutation subtypes in a single-institution cohort of patients with AML.
Methods
We retrospectively analyzed 101 consecutive adults with NPM1-mutated AML at Mayo Clinic, Rochester. At diagnosis cytogenetic and molecular profiling were assigned through conventional karyotyping and next-generation sequencing (NGS), respectively. NPM1 mutation subtype was assessed using NGS in conjunction with qualitative DNA-based testing with reflex RNA-based reverse transcription-polymerase chain reaction (RT-PCR) according to institutional protocol. Measurable residual disease testing (MRD) was performed by multiparameter flow cytometry in all patients, as well as by NPM1 RT-PCR in patients with type A, B, or D mutations from bone marrow aspirate sample after induction therapy. Overall survival (OS) and leukemia-free survival (LFS) were estimated by Kaplan-Meier method and calculated from date of diagnosis. Relapse incidence was assessed using competing-risk analysis accounting for death as a competing event.
Results
The study cohort included 70 (69%) patients with type A, 7 (7%) with type B, 3 (3%) with type D, and 21 (21%) with non-ABD NPM1-mutations. Median age was 68 years (range:32–85), and 44% were male. Given the limited number of informative patients with type B and D cases, these variants were grouped with type A for subsequent analyses. Clinical and laboratory features were comparable between ABD and non-ABD groups, including presenting white blood cell count (median 20 vs 36 ×10?/L; P=0.12), frequency of abnormal cytogenetics (15% vs 19%), secondary AML (8% vs 5%), therapy-related AML (11% vs 10%), NPM1 variant allele fraction (median 34% vs 33%, p=0.7), and European LeukemiaNet (ELN) 2022 adverse-risk disease (14% vs 14%). The distribution of co-mutations was also similar, with FLT3-ITD (44% vs 24%; P=0.08), DNMT3A (35% vs 24%; P=0.3), IDH2 (19% vs 24%; P=0.7), and IDH1(13% vs 10%; P=0.7) representing the most frequent molecular abnormalities. Prevalence of myelodysplasia-related gene mutations was also similar between the two groups (15 vs 24%, p=0.35).
At a median follow-up of 35 months among surviving patients, 46 (45%) deaths and 27 (26%) relapses were documented. Treatment allocation was comparable between groups and included intensive chemotherapy (60% vs 61%) and allogeneic stem cell transplant (alloHCT, 36% vs 38%) in ABD vs non-ABD groups. Composite remission rates following intensive therapy (75% vs 100%) and non-intensive therapy (71% vs 67%), as well as flow cytometric MRD negativity and molecular NPM1 MRD clearance, were similar between ABD and non-ABD groups. Similarly, median OS (56 vs 24 months, p=0.5) and LFS (19 vs 17 months, p=0.3) were comparable, while cumulative incidence of relapse at 3 and 5 years was numerically higher in the non-ABD group (47% vs 30% at 3 years, and 64% vs 30% at 5 years, p=0.12).
On univariate analysis, older age, non-intensive therapy, higher presenting white blood cell count, ELN 2022 adverse-risk disease, and TET2 mutation were associated with inferior OS, whereas IDH2 mutation was associated with improved OS. NPM1 mutation subtype was not associated with OS. AlloHCT was not associated with improved OS in the overall cohort as well as patients achieving NPM1 molecular MRD negatively after induction. In contrast, among patients with persistent NPM1 molecular positivity (N=39), alloHCT was associated with improved OS (median 56 vs 25 months; P=0.028).
Conclusion
NPM1 mutation subtypes were associated with similar clinical and molecular characteristics, response to therapy, MRD clearance, and survival outcomes. These observations support current approach of risk stratification based on established clinical, molecular, and MRD-based risk factors in NPM1 mutated patients.
DISCLOSURES
Saubia Fathima, MD: No relevant conflicts of interest to declare.